GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Gross Profit

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Gross Profit : $0.74 Mil (TTM As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Gross Profit?

Comera Life Sciences Holdings's gross profit for the three months ended in Sep. 2023 was $0.09 Mil. Comera Life Sciences Holdings's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $0.74 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Comera Life Sciences Holdings's gross profit for the three months ended in Sep. 2023 was $0.09 Mil. Comera Life Sciences Holdings's Revenue for the three months ended in Sep. 2023 was $0.14 Mil. Therefore, Comera Life Sciences Holdings's Gross Margin % for the quarter that ended in Sep. 2023 was 69.12%.

Comera Life Sciences Holdings had a gross margin of 69.12% for the quarter that ended in Sep. 2023 => Durable competitive advantage

During the past 3 years, the highest Gross Margin % of Comera Life Sciences Holdings was 76.52%. The lowest was 49.69%. And the median was 66.82%.


Comera Life Sciences Holdings Gross Profit Historical Data

The historical data trend for Comera Life Sciences Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Gross Profit Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Gross Profit
0.34 0.16 0.42

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.17 0.11 0.28 0.26 0.09

Competitive Comparison of Comera Life Sciences Holdings's Gross Profit

For the Biotechnology subindustry, Comera Life Sciences Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Gross Profit falls into.



Comera Life Sciences Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Comera Life Sciences Holdings's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0.633 - 0.21
=0.42

Comera Life Sciences Holdings's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=0.136 - 0.042
=0.09

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.74 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Comera Life Sciences Holdings's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.09 / 0.136
=69.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Comera Life Sciences Holdings  (OTCPK:CMRA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Comera Life Sciences Holdings had a gross margin of 69.12% for the quarter that ended in Sep. 2023 => Durable competitive advantage


Comera Life Sciences Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Executives
Michael Gerard Campbell officer: Chief Financial Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
David Soane 10 percent owner C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney officer: Chief Scientific Officer 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr. director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt officer: Chief Business Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman director, officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp 10 percent owner 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Headlines